HOPE Therapeutics Inc.

About HOPE Therapeutics Inc.

HOPE Therapeutics is dedicated to providing breakthrough mental healthcare for conditions such as depression, suicidality, PTSD, anxiety, and OCD. They leverage innovative neuroplastic therapies like TMS, IV Ketamine, and SPRAVATO(r), combined with psychotherapy and psychiatry, to establish a new standard for personalized mental health care. The company is building a nationwide network of clinics offering transformative treatments and next-generation psychedelic medicines and digital therapeutics.

Products & Services

IV Ketamine Therapy:A transformative treatment for depression and other mood disorders, discovered in the early 2000s for its powerful antidepressant effects at subanesthetic doses. It is considered a significant advancement in psychiatry.

Transcranial Magnetic Stimulation (TMS):A non-invasive treatment effective for depression, OCD, anxiety, and smoking cessation, using focused magnetic fields to stimulate targeted brain areas over brief clinic sessions.

SPRAVATO(r) (Intranasal Esketamine):The first FDA-approved nasal spray medication for adults with treatment-resistant depression (TRD), shown to treat Major Depressive Disorders more quickly and effectively than many antidepressants.

Specialties

Neuroplastic Therapies Mental Health Treatment IV Ketamine Therapy Transcranial Magnetic Stimulation (TMS) SPRAVATO(r) (Intranasal Esketamine) Psychotherapy Psychiatry

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 7800000 MR: - FA: $7.8 million FAN: 7800000	D: 2025-05-15 FD: 2025-05-15	1 investors
2	RT: Series A Convertible Preferred Stock T: - FT: Series A Convertible Preferred Stock	A: 2500000 MR: - FA: $2.5 million FAN: 2500000	D: 2025-04-03 FD: 2025-04-03	1 investors
3	RT: Series A T: - FT: Series A	A: 27000000 MR: - FA: $27 million FAN: 27000000	D: 2025-01-06 FD: 2025-01-06	1 investors
4	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 1500000 MR: - FA: 1,500,000 FAN: 1500000	D: 2024-02-27 FD: 2024-02-27	2 investors

Debt Latest

2025-05-15

$7.8M

1 investor (Pro only)

Series A Convertible Preferred Stock 2025-04-03

$2.5M

Series A 2025-01-06

$27.0M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David Feifel

Incoming Chief Medical Innovation Officer

S

Sanjay Gupta

Recent News